ETF Comparison: 2B78 vs ESIH
ETFã®èª¬æ
2B78 - iShares Healthcare Innovation UCITS ETF
The iShares Healthcare Innovation UCITS ETF is an equity fund that tracks the iSTOXX FactSet Breakthrough Healthcare index, investing in companies worldwide that are focused on innovation in global healthcare services. The fund has a total expense ratio of 0.40% and uses a sampling technique to replicate the performance of the underlying index. It is a large fund with assets under management of 982 million Euro, launched in 2016 and domiciled in Ireland.
ESIH - iShares MSCI Europe Health Care Sector UCITS ETF EUR (Acc)
The iShares MSCI Europe Health Care Sector UCITS ETF EUR (Acc) is an exchange-traded fund that tracks the MSCI Europe Health Care 20/35 Capped index, providing investors with exposure to large and mid-cap European companies from the health care sector. The fund is domiciled in Ireland, has a total expense ratio of 0.18%, and distributes dividends by accumulating and reinvesting them.
æ¯èŒããŒãã«
| 2B78 | ESIH | |
|---|---|---|
| ãã¡ã³ãå | iShares Healthcare Innovation UCITS ETF | iShares MSCI Europe Health Care Sector UCITS ETF EUR (Acc) |
| Fund Provider | BlackRock | BlackRock |
| Index | iSTOXX® FactSet Breakthrough Healthcare | MSCI Europe Health Care 20/35 Capped |
| Asset Class | Equity | Equity |
| Listing | EU-listed | EU-listed |
| Expense Ratio | 0.4% | 0.18% |
| Inception Date | 2016-09-08 | 2020-11-17 |
| Number Of Holdings | 195 | 42 |
| Currency | USD | EUR |
| Distribution Policy | Accumulating | Accumulating |
| Region | Global | Europe |
| Market Cap | Blend | Blend |
| Sector | Healthcare | Healthcare |
| Leveraged | Non-leveraged | Non-leveraged |
ããã¯ãã¹ããªãã·ã§ã³
ãµããªãŒ
äž»èŠææš
ããã©ãŒãã³ã¹ææš
ãªã¹ã¯ææš
詳现ãªã¿ãŒã³
ããã©ãŒãã³ã¹åæ
ããã©ãŒãã³ã¹åæã¯ã环ç©ãªã¿ãŒã³ã幎æ«ïŒEoYïŒãªã¿ãŒã³ãSharpeã¬ã·ãªãSortinoã¬ã·ãªãªã©ã®ãªã¹ã¯èª¿æŽæžã¿ææšãéããŠãæè³æŠç¥ã®ãªã¿ãŒã³ãè©äŸ¡ããããã«éå»ããŒã¿ãè©äŸ¡ããŸããããã«ãããæè³å®¶ã¯ããŸããŸãªåžå Žç°å¢ã§ã®çµ¶å¯Ÿçããã³çžå¯Ÿçãªããã©ãŒãã³ã¹ãè©äŸ¡ã§ããŸãã
环ç©ãªã¿ãŒã³
幎æ«ãªã¿ãŒã³ããŒãã«
幎æ«ãªã¿ãŒã³
ãªã¹ã¯åæ
ãªã¹ã¯åæãšã¯ãè³æ¬ã®æå€±ã«ã€ãªããå¯èœæ§ã®ããæœåšçãªãã¬ãã£ãã€ãã³ãã®è©äŸ¡ãæããŸãããªã¹ã¯åæã宿œããããšã§ãæè³ãè¡ãã¹ããã©ããã®å€æã«åœ¹ç«ãŠãããšãã§ããŸããããã¯ãæè³æŠç¥ã®äžè²«æ§ã«å¯Ÿããå©å®³é¢ä¿è ã®ä¿¡é Œãåæ ãããããŒããŠã³ããã©ãã£ãªãã£ãããŒã¿ãªã©ã®ãªã¹ã¯ææšã䜿çšããŠè¡ãããŸãã
ãããŒããŠã³
ãããŒããŠã³ããŒãã«
ã¢ã³ãã«ã«ãã·ãã¥ã¬ãŒã·ã§ã³
ã¢ã³ãã«ã«ãã·ãã¥ã¬ãŒã·ã§ã³ã¯ãéå»ã®è³ç£äŸ¡æ ŒããŒã¿ããã®ã©ã³ãã ãµã³ããªã³ã°ãéããŠå¹ åºãæœåšçãªçµæãçæããããšã§ãããŒããã©ãªãªã®ãªã¿ãŒã³ãäºæž¬ããããã«äœ¿çšãããçµ±èšçææ³ã§ããããŸããŸãªåžå Žæ¡ä»¶äžã§ã®ããŒããã©ãªãªã®æœåšçãªãªã¹ã¯ãšãªã¿ãŒã³ãè©äŸ¡ããã®ã«åœ¹ç«ã¡ãŸãããã®ã·ãã¥ã¬ãŒã·ã§ã³ã¯åææè³ãèæ ®ããå®é¡ç©ç«ãå®é¡åŒãåºããå²ååŒãåºããªã©ã®ãã£ãã·ã¥ãããŒã·ããªãªããªãã·ã§ã³ã§ã·ãã¥ã¬ãŒãããŸãã
éèŠïŒã¢ã³ãã«ã«ãã·ãã¥ã¬ãŒã·ã§ã³ã«ãã£ãŠçæãããäºæž¬ã¯çŽç²ã«ä»®èª¬çãªãã®ã§ãããå°æ¥ã®ãªã¿ãŒã³ãä¿èšŒãããã®ã§ã¯ãããŸãããæè³å€æã¯ããŸããŸãªèŠå ãèæ ®ããäžã§è¡ãã¹ãã§ãããéå»ã®ããã©ãŒãã³ã¹ã¯å°æ¥ã®çµæã瀺ããã®ã§ã¯ãããŸããã